Pharsight

Drugs that contain Nintedanib Esylate

1. List of Ofev drug patents

OFEV's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(10 months from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Dec, 2025

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 6, 2026
New Indication (I) Mar 9, 2023

Market Authorisation Date: 15 October, 2014

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's patent expiration?
More Information on Dosage

OFEV family patents

20

United States

15

European Union

6

Norway

6

Japan

5

Denmark

5

Australia

5

Slovenia

5

Argentina

5

Portugal

5

Spain

5

Korea, Republic of

5

Poland

5

China

4

South Africa

4

Mexico

4

Lithuania

4

Hungary

4

Brazil

4

Croatia

4

Cyprus

4

Peru

4

Taiwan, Province of China

4

Ukraine

EA

4

EA

4

Canada

4

New Zealand

3

Israel

3

Uruguay

3

Malaysia

3

RS

3

Ecuador

2

Hong Kong

2

Morocco

2

Colombia

2

Chile

2

Tunisia

2

ME

1

Austria

1

Turkey

1

Egypt

1

Saudi Arabia

1

Belgium

1

Germany

1

Singapore

YU

1

Yugoslavia

1

Luxembourg

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic